nach oben

The European Journal of Health Economics

Erschienen in:

10.01.2023 | Original Paper

Population norms in France with EQ-5D-5L: health states, value indexes, and VAS

verfasst von: Laurène Gautier, Jessica Azzi, Grèce Saba, Geneviève Bonnelye, Gérard de Pouvourville

Erschienen in: The European Journal of Health Economics | Ausgabe 9/2023

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To provide EuroQoL EQ-5D-5L French population norms based on a sample of 15,000 responders.

Methods

Based on the National Health and Wellness Survey, an international, annual, selfadministered Internet-based survey, this study extracted data from France for 2018 involving a sample of 15,000 respondents stratified by age and gender. Responses to the EQ-5D-5L questionnaire and the Visual Analog Scale (VAS) score, together with sociodemographic, health behavior, and disease status variables were collected. VAS, value indexes, the level sum score, and the distribution of levels per dimension were described. Multivariate regression analyses were performed to identify covariates with a statistically significant effect on the five dimensions and the three scores.

Results

The mean [standard deviation (SD)] VAS was 73.4 (22.2) for the entire sample (male 74.8 vs female 72.2, p < 0.0001). The Mean SD value index was 0.905 (0.158) (male 0.915 vs female 0.895, p < 0.0001). The mean SD level sum score was 7.6 (3.0) (7.4 for males vs. 7.9 for females p < 0.0001). Health state 11,111 (no problem in any dimension) represented 25.1% of all responses. “No problem” responses’ proportions were Self Care (91.3%), Usual Activities (74.2%), Mobility (72.4%), Anxiety/Depression (52.6%) and Pain/Discomfort (37.7%). Multivariate regressions revealed a significant relationship for health states, value indexes, and VAS with age, income, employment, marital status, smoking and alcohol consumption, obesity, and the presence of one or more health problems.

Conclusion

Based on a large sample, this study is the first to report EQ-5D-5L population norms for France.

Nur mit Berechtigung zugänglich

Szende, A., Janssen, B., & Cabases, J. (eds.). Self-Reported Population Health: An International Perspective based on EQ-5D. Springer, Amsterdam. https://doi.org/10.1007/978-94-007-7596-1 (2014)

Herdman, M., Gudex, C., Lloyd, A., Janssen, M., Kind, P., Parkin, D., Badia, X.: Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual. Life Res. 20(10), 1727–1736 (2011). https://doi.org/10.1007/s11136-011-9903-xCrossRefPubMedPubMedCentral

König, H.-H., Bernert, S., Angermeyer, M.C., Matschinger, H., Martinez, M., Vilagut, G., ESEMeD/MHEDEA 2000 Investigators: Comparison of population health status in six European countries: results of a representative survey using the EQ-5D questionnaire. Med. Care 47(2), 255–261 (2009). https://doi.org/10.1097/MLR.0b013e318184759eCrossRefPubMed

Janssen, M.F., Szende, A., Cabases, J., Ramos-Goñi, J.M., Vilagut, G., König, H.H.: Population norms for the EQ-5D-3L: a cross-country analysis of population surveys for 20 countries. Eur. J. Health Econ. HEPAC Health Econ. Prev. Care 20(2), 205–216 (2019). https://doi.org/10.1007/s10198-018-0955-5CrossRef

Chevalier, J., de Pouvourville, G.: Valuing EQ-5D using time trade-off in France. Eur. J. Health Econ. 14(1), 57–66 (2013). https://doi.org/10.1007/s10198-011-0351-x. (Epub 2011 Sep 21. PMID: 21935715)CrossRefPubMed

National Health and Wellness Survey NHWS—Cerner Enviza. (n.d.). https://www.cernerenviza.com/real-world-data/national-health-and-wellness-survey-nhws. Retrieved 24 June 2022

Andrade, L.F., Ludwig, K., Goni, J.M.R., Oppe, M., de Pouvourville, G.: A French value set for the EQ-5D-5L. Pharmacoeconomics 38(4), 413–425 (2020). https://doi.org/10.1007/s40273-019-00876-4CrossRefPubMedPubMedCentral

Gupta, S., Richard, L., Forsythe, A.: The humanistic and economic burden associated with increasing body mass index in the EU5. Diabetes Metab. Syndrome Obes. Targets Ther. 8, 327–338 (2015). https://doi.org/10.2147/DMSO.S83696CrossRef

Gupta, S., Kwan, P., Faught, E., Tsong, W., Forsythe, A., Ryvlin, P.: Understanding the burden of idiopathic generalized epilepsy in the United States, Europe, and Brazil: an analysis from the National Health and Wellness Survey. Epilepsy Behav. 55, 146–156 (2016). https://doi.org/10.1016/j.yebeh.2015.12.018CrossRefPubMed

10.

Gupta, S., Ryvlin, P., Faught, E., Tsong, W., Kwan, P.: Understanding the burden of focal epilepsy as a function of seizure frequency in the United States, Europe, and Brazil. Epilepsia Open 2(2), 199–213 (2017). https://doi.org/10.1002/epi4.12050CrossRefPubMedPubMedCentral

11.

Gruenberger, J.-B., Vietri, J., Keininger, D.L., Mahler, D.A.: Greater dyspnea is associated with lower health-related quality of life among European patients with COPD. Int. J. Chron. Obstruct. Pulmon. Dis. 12, 937–944 (2017). https://doi.org/10.2147/COPD.S123744CrossRefPubMedPubMedCentral

12.

Charlson, M.E., Pompei, P., Ales, K.L., MacKenzie, C.R.: A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J. Chronic Dis. 40(5), 373–383 (1987). https://doi.org/10.1016/0021-9681(87)90171-8CrossRefPubMed

13.

Home-Eurostat. (n.d.). https://ec.europa.eu/eurostat. Retrieved 30 Mar 2021

14.

Tobin, J.: Estimation of relationships for limited dependent variables. Econometrica 26(1), 24–36 (1958). https://doi.org/10.2307/1907382CrossRef

15.

Tobit Models|R Data Analysis Examples. (n.d.). https://stats.idre.ucla.edu/r/dae/tobit-models/. Retrieved 22 July 2021

16.

McCaffrey, N., Kaambwa, B., Currow, D.C., Ratcliffe, J.: Health-related quality of life measured using the EQ-5D–5L: South Australian population norms. Health Qual. Life Outcomes 14(1), 133 (2016). https://doi.org/10.1186/s12955-016-0537-0CrossRefPubMedPubMedCentral

17.

Scalone, L., Cortesi, P.A., Ciampichini, R., Cesana, G., Mantovani, L.G.: Health-related quality of life norm data of the general population in Italy: results using the EQ-5D-3L and EQ-5D-5L instruments. Epidemiol. Biostat. 2015(12), 3 (2015)

18.

Shiroiwa, T., Fukuda, T., Ikeda, S., Igarashi, A., Noto, S., Saito, S., et al.: Japanese population norms for preference-based measures: EQ-5D-3L, EQ-5D-5L, and SF-6D. Qual. Life Res. 25(3), 707–719 (2016)CrossRefPubMed

19.

Garcia-Gordillo, M.A., Adsuar, J.C., Olivares, P.R.: Normative values of EQ-5D-5L: in a Spanish representative population sample from Spanish Health Survey, 2011. Qual. Life Res. 25(5), 1313–1321 (2016)CrossRefPubMed

20.

Feng, Y., Devlin, N., Herdman, M.: Assessing the health of the general population in England: how do the three- and five-level versions of EQ-5D compare? Health Qual. Life Outcomes 21(13), 171 (2015)CrossRef

Titel: Population norms in France with EQ-5D-5L: health states, value indexes, and VAS
verfasst von: Laurène Gautier
Jessica Azzi
Grèce Saba
Geneviève Bonnelye
Gérard de Pouvourville
Publikationsdatum: 10.01.2023
Verlag: Springer Berlin Heidelberg
Erschienen in: The European Journal of Health Economics / Ausgabe 9/2023
Print ISSN: 1618-7598
Elektronische ISSN: 1618-7601
DOI: https://doi.org/10.1007/s10198-022-01559-2

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Springer Medizin

Population norms in France with EQ-5D-5L: health states, value indexes, and VAS

Abstract

Purpose

Methods

Results

Conclusion

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2023

Early start of anti-dementia medication is associated with lower health and social care costs in Alzheimer´s patients: a Finnish nationwide register study

Does uptake of specialty care affect HRQoL development in COPD patients beneficially? A difference-in-difference analysis linking claims and survey data

Public preferences for policies promoting a healthy diet: a discrete choice experiment

The social value of gambling: surplus estimates by gambling types for France

A European multinational cost-effectiveness analysis of empagliflozin in heart failure with reduced ejection fraction

Cost-effectiveness of ravulizumab compared with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria in the Netherlands